Literature DB >> 2645367

Psoriatic epidermal cells demonstrate increased numbers and function of non-Langerhans antigen-presenting cells.

O Baadsgaard1, A K Gupta, R S Taylor, C N Ellis, J J Voorhees, K D Cooper.   

Abstract

The recent findings that the immunosuppressant cyclosporine A (CsA) improves psoriasis raises the possibility that cellular immune processes play a major role in the pathogenesis of psoriasis. We therefore investigated the phenotype and function of cells within psoriatic epidermis that can play a role in cellular immunologic reactivity. Double fluorescence microscopic studies with monoclonal antibodies of epidermal cells in suspension (EC) and of histologic sections demonstrated that involved psoriatic skin contained a significantly increased number of non-Langerhans cell T6-DR+ EC (4.9 + 2.1%) relative to uninvolved (0.3 +/- 0.1%), p less than 0.01. This non-Langerhans cell population was comprised of DR+ monocytes, DR+ activated T lymphocytes, a few DR+RFD1+ antigen-presenting cells (APC), and DR+ keratinocytes. Langerhans cell (LC) levels in EC suspension were not different between involved and uninvolved psoriatic epidermis. Functional studies demonstrated that involved psoriatic epidermal cells had an increased capacity to induce T-cell activation and proliferation relative to uninvolved EC (p less than 0.04). This increased APC activity was due to the non-LC T6-DR+HLe1+ APC population and not to DR+ keratinocytes. These results demonstrate that involved psoriatic epidermal cells contain both an increased number and function of antigen-presenting cells. The pathogenetic mechanisms in psoriasis may be related to ongoing cellular immune responses in the skin, and the effect of CsA may be mediated through a suppressive effect on the enhanced antigen-presenting cell activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2645367     DOI: 10.1111/1523-1747.ep12276718

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  15 in total

Review 1.  Immunological mechanisms involved in psoriasis.

Authors:  C E Griffiths; J J Voorhees
Journal:  Springer Semin Immunopathol       Date:  1992

2.  Kinetics and regulation of human keratinocyte stem cell growth in short-term primary ex vivo culture. Cooperative growth factors from psoriatic lesional T lymphocytes stimulate proliferation among psoriatic uninvolved, but not normal, stem keratinocytes.

Authors:  Z Bata-Csorgo; C Hammerberg; J J Voorhees; K D Cooper
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

3.  Lesional psoriatic T cells contain the capacity to induce a T cell activation molecule CDw60 on normal keratinocytes.

Authors:  L Skov; L S Chan; D A Fox; J K Larsen; J J Voorhees; K D Cooper; O Baadsgaard
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

4.  Influence of systemic cyclosporin A on interleukin-2 and epidermal growth factor receptor expression in psoriatic skin lesions.

Authors:  A Horroccks; A D Ormerod; J I Duncan; A W Thomson
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

Review 5.  The skin immune system and psoriasis.

Authors:  S M Breathnach
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

6.  Lymphocytes and macrophages of the epidermis and dermis in lesional psoriatic skin, but not epidermal Langerhans cells, are depleted by treatment with cyclosporin A.

Authors:  A K Gupta; O Baadsgaard; C N Ellis; J J Voorhees; K D Cooper
Journal:  Arch Dermatol Res       Date:  1989       Impact factor: 3.017

7.  Interleukin-1 receptor antagonist in normal and psoriatic epidermis.

Authors:  C Hammerberg; W P Arend; G J Fisher; L S Chan; A E Berger; J S Haskill; J J Voorhees; K D Cooper
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

8.  A spontaneous mutation characterized by chronic proliferative dermatitis in C57BL mice.

Authors:  H HogenEsch; M J Gijbels; E Offerman; J van Hooft; D W van Bekkum; C Zurcher
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

9.  Tacrolimus (FK 506)--a new therapeutic agent for severe recalcitrant psoriasis.

Authors:  B V Jegasothy; C D Ackerman; S Todo; J J Fung; K Abu-Elmagd; T E Starzl
Journal:  Arch Dermatol       Date:  1992-06

10.  Production of type-1 and type-2 cytokines by peripheral blood mononuclear cells of psoriatic patients.

Authors:  N Mozzanica; A Cattaneo; D Trabattoni; A F Finzi; E Schmitt; E Ferrario; M Clerici; G Vignati; M L Villa
Journal:  Immunology       Date:  1995-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.